DM1Research retweeted
MDF’s new DM1 and DM2 Guides are here! 💚
We’ve reworked and expanded our previous toolkit to create guides for people living with #MyotonicDystrophy, their caregivers, and loved ones.
Explore practical information about DM, medical care, and daily life.
At PepGen, we value providing the DM1 community with timely and transparent updates on our progress. Today we announced interim results from the FREEDOM2-DM1 clinical trial.
Read our latest letter to the DM1 community here: pepgen.co/4iL0xTQ
Thank you to those who have participated in trials, are considering participation, or supporting loved ones. Our work is not possible without you.
#myotonicdystrophy #DM1
DM1Research retweeted
$PEPG PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures | PepGen investors.pepgen.com/news-re…
DM1Research retweeted
Share your thoughts on #myotonicDystrophy clinical trials with a 5-minute survey! Your feedback will help MDF understand what information is most important to the DM community as trials continue to develop. myotonicdistribution.qualtri…
DM1Research retweeted
In an analysis of almost one million genomes, Rahman et al. find that myotonic dystrophy type 1 is more common than previously recognised, with pathogenic DMPK repeat expansions present in about 1 in 1,500 people. shorturl.at/it6Ka
DM1Research retweeted
$DYN Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
globenewswire.com/news-relea…
DM1Research retweeted
IFN1 activation is normally a cellular antiviral response.
In myotonic dystrophy, the trigger may be the cell’s own faulty mRNA, according to a small cell study pointing to a possible drug target. 🧫 💪
buff.ly/EgcrhVh
DM1Research retweeted
.@UF study in @jclinicalinvest unveils mechanisms driving pain in myotonic disorders, in which muscles have difficulty relaxing after contraction. Preclinical results also suggest that an already FDA-approved nonopioid drug might offer relief from myotonia-associated pain.
Read more: bit.ly/4xKQSlz
DM1Research retweeted
Dyne Therapeutics has shared a message to the #myotonicDystrophycommunity reaffirming its commitment to DM1 research and to advancing z-basivarsen (DYNE-101), an investigational therapy currently being evaluated in two ongoing global clinical trials: dyne-tx.com/message-to-the-g…
DM1Research retweeted
Brookville, Indiana, put International #MyotonicDystrophy Awareness Day on the map! Thank you to Jessica Ison, along with family and friends for spreading awareness! myotonic.org/events/internat…
DM1Research retweeted
The global #myotonicDystrophy patient advocacy community is asking Novartis to complete its analysis of the HARBOR data, explore the secondary and exploratory findings, and not abandon DM.
Read the open letter at myotonic.org/an-open-letter-…
DM1Research retweeted
Replying to @Novartis
@Novartis announced that the phase 3 HARBOR study evaluating investigational delpacibartetedesiran (del-desiran; formerly AOC 1001) in people with myotonic dystrophy type 1 did not meet its primary endpoint of video hand opening time, a measure of hand myotonia.
Novartis confirmed evidence of clinical activity that was observed in secondary endpoints and exploratory analyses, with full study data undergoing further evaluation.
Details: hubs.li/Q04x1FvF0
DM1Research retweeted
CRISPR/dCas9-mediated tuning of DMPK transcription reveals a quantitative relationship between toxic repeat RNA expression and MBNL1 activity in myotonic dystrophy doi.org/10.1093/hmg/ddag079
DM1Research retweeted
Novartis announced that the Phase 3 HARBOR trial of del-desiran for myotonic dystrophy type 1 did not meet its primary endpoint. MDF stands with our community as clinical trials continue to progress. Read MDF's statement: myotonic.org/myotonic-dystro…
DM1Research retweeted
I feel awful for the DM1 community this morning after the del-desiran failure. No disease-modifying therapeutics have been approved and it seems like it'll stay that way for longer.
I am frankly shocked del-desiran failed. When I first heard of the program years ago, I was confused why they'd use an siRNA; in DM1 you try to get rid of toxic DMPK granules in the nucleus, so this is one of the times you should choose an ASO. But Avidity's data always looked good, so I figured there must be some sort of mass action thing going on, shifting DMPK RNA out of the nucleus.
Without any data released, it's hard to Monday Morning QB this. But one thing I'd look for is patient characteristics; DM1 is highly heterogenous, and it's possible they got unlucky with high patient-to-patient variability. Other questions:
- What were the results/correlation across knockdown in biopsy -> splicing changes -> vHOT?
- What was safety like, and was there any anemia etc.?
- Did del-desiran benefit patients with a certain number of repeats between X and Y, but not other ranges?
I still think TfR is a viable target for RNA delivery vehicles, in general and also because Novartis noted there were "signs of clinical activity" on secondary and exploratory endpoints. But the premium today has gone up on alternatives like integrin or ENT2 (but should not for CPPs and the like)
For Tara, DM1 was once an unknown name behind a growing list of unexplained symptoms.
Early cataracts. Fatigue. Brain fog. Stiffness in her hands. Signs that were easy to explain away until her nephew’s diagnosis helped her family begin connecting the dots.
Tara is a biologist, teacher, mother, advocate, and person living with DM1. Her story reminds us that rare disease is never just a diagnosis. It is a family story, a daily reality, and a call to listen more closely to the people living it.
Read Tara’s story: pepgen.co/4xLA8Ls
DM1Research retweeted
This study characterized the natural history of adult-onset myotonic dystrophy type 1 over two years and evaluated quantitative MRI and clinical outcome measures for use in clinical trials. Read more: hubs.la/Q04tMfvG0
DM1Research retweeted
CRISPR/dCas9-mediated tuning of DMPK transcription reveals a quantitative relationship between toxic repeat RNA expression and MBNL1 activity in myotonic dystrophy dlvr.it/TV6tmv #HumMolGenet
DM1Research retweeted
Meet 2025 MDF Pilot Grant Recipients David Housman, PhD, and Christopher Ng, ScD! 🧬✨
Their MDF-funded project adapts DNA repair enzyme therapy to study repeat instability in #myotonicDystrophy type 1 (#DM1) and support therapy development.
Learn more: myotonic.org/2025-pilot-gran…




























